Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert R Henry

Showing results (131-140 of 155) with videos related to

Pageof 16
Sort By:
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|February 26, 2013
The clinical approach to the detection of lipodystrophy - an AACE consensus statementYehuda Handelsman, Elif A Oral, Zachary T Bloomgarden, et al.
JAMA|April 1, 2014
Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trialA Michael Lincoff, Jean-Claude Tardif, Gregory G Schwartz, et al.
The Journal of Clinical Investigation|March 12, 2011
Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistanceWanzhu Jin, Allison B Goldfine, Tanner Boes, et al.
The New England Journal of Medicine|September 14, 2017
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 DiabetesSatish K Garg, Robert R Henry, Phillip Banks, et al.
The Journal of Clinical Endocrinology and Metabolism|March 17, 2016
Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOWDevjit Tripathy, Dawn C Schwenke, MaryAnn Banerji, et al.
Nature|April 24, 2012
A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasisJohan W Jonker, Jae Myoung Suh, Annette R Atkins, et al.
The Journal of Clinical Endocrinology and Metabolism|June 16, 2005
Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphismDaniel T O'Connor, Peter E Cadman, Clayton Smiley, et al.
Diabetes Care|April 8, 2014
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOWDevjit Tripathy, Stephen C Clement, Dawn C Schwenke, et al.
Diabetes|July 19, 2013
Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlatesRalph A Defronzo, Devjit Tripathy, Dawn C Schwenke, et al.
Diabetes Care|September 25, 2013
Prediction of diabetes based on baseline metabolic characteristics in individuals at high riskRalph A Defronzo, Devjit Tripathy, Dawn C Schwenke, et al.
Pageof 16

Showing results (131-140 of 155) with videos related to

Sort By:
Pageof 16
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|February 26, 2013
The clinical approach to the detection of lipodystrophy - an AACE consensus statementYehuda Handelsman, Elif A Oral, Zachary T Bloomgarden, et al.
JAMA|April 1, 2014
Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trialA Michael Lincoff, Jean-Claude Tardif, Gregory G Schwartz, et al.
The Journal of Clinical Investigation|March 12, 2011
Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistanceWanzhu Jin, Allison B Goldfine, Tanner Boes, et al.
The New England Journal of Medicine|September 14, 2017
Effects of Sotagliflozin Added to Insulin in Patients with Type 1 DiabetesSatish K Garg, Robert R Henry, Phillip Banks, et al.
The Journal of Clinical Endocrinology and Metabolism|March 17, 2016
Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOWDevjit Tripathy, Dawn C Schwenke, MaryAnn Banerji, et al.
Nature|April 24, 2012
A PPARγ-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasisJohan W Jonker, Jae Myoung Suh, Annette R Atkins, et al.
The Journal of Clinical Endocrinology and Metabolism|June 16, 2005
Pancreastatin: multiple actions on human intermediary metabolism in vivo, variation in disease, and naturally occurring functional genetic polymorphismDaniel T O'Connor, Peter E Cadman, Clayton Smiley, et al.
Diabetes Care|April 8, 2014
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOWDevjit Tripathy, Stephen C Clement, Dawn C Schwenke, et al.
Diabetes|July 19, 2013
Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlatesRalph A Defronzo, Devjit Tripathy, Dawn C Schwenke, et al.
Diabetes Care|September 25, 2013
Prediction of diabetes based on baseline metabolic characteristics in individuals at high riskRalph A Defronzo, Devjit Tripathy, Dawn C Schwenke, et al.
Pageof 16